Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PMCB with free AI briefings, catalyst countdowns, and dilution alerts.

PMCB · PharmaCyte Biotech, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$17.8M Cash on Hand
49.2mo Cash Runway
Follow PMCB by email Get an email when PMCB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PMCB, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

PMCB holds $17.8M in cash and short-term investments (as of Jul 31, 2026) and burns about $1.1M/quarter from operations, an estimated runway of 49.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 20 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PMCB files for a raise →

👥 Who Owns PMCB

Insiders 6.9% Other 5%+ holders 45.9% Institutions (33 holders) 7.5% Public and other holders 39.7%
HolderTypeShares% of sharesAs of
PharmaCyte Biotech, Inc. 5%+ holder (13G) 4,932,825 45.95% 2026-03-17
Joshua Silverman
CEO and President, Director · +170,000 options
Insider 466,250 4.34% 2026-01-05
Jonathan Schechter
Director · +281,660 options
Insider 192,500 1.79% 2026-01-05
Robert Weinstein
Director · +281,660 options
Insider 41,250 0.38% 2025-04-25
Michael M Abecassis
Director · +281,660 options
Insider 23,092 0.22% 2025-04-25
Wayne Remell Walker
Director · +281,660 options
Insider 20,625 0.19% 2025-04-25

Share count 10,735,649 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full PMCB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PMCB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.